Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a cytopathologically or histopathologically confirmed diagnosis of an advanced solid tumor, excluding breast cancer which has progressed despite standard therapy or for which no standard therapy exists
ECOG performance status 0 or 1 and anticipated life expectancy ≥ 3 months
Patient must meet protocol-specific laboratory values
You may not be if
Patients with brain metastases
Patients who have received or who are expected to receive any prohibited medications and therapies
Patients who have received CYP1A2 inducer, CYP2C9/2C19 inducer or CYP3A4 inducer medications within 30 days prior to start study treatment or are expected to receive during the first 14 days after starting the study treatment
Patients with a known hypersensitivity to benzodiazepines
Patients who have not recovered from previous anti-cancer therapies
Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of TKI258
Patients who have concurrent severe and/or uncontrolled concomitant medical conditions that could compromise participation in the study
Female patients who are pregnant or breast-feeding
Fertile males or women not willing to use highly effective methods of contraception
